Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulatory Drugs in the Management of SARS-CoV-2
Daniel Burrage, Soraya Koushesh, Nidhi Sofat
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Viral targets for vaccines against COVID-19
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1055
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models
Yingjun Li, Liu Cao, Ge Li, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2785-2793
Closed Access | Times Cited: 124
Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications
Adekunle Babajide Rowaiye, Okiemute Ajiroghene Okpalefe, Olukemi Onuh Adejoke, et al.
Journal of Inflammation Research (2021) Vol. Volume 14, pp. 1487-1510
Open Access | Times Cited: 71
COVID-19 in the elderly people and advances in vaccination approaches
Kuldeep Dhama, Shailesh Kumar Patel, Senthilkumar Natesan, et al.
Human Vaccines & Immunotherapeutics (2020) Vol. 16, Iss. 12, pp. 2938-2943
Open Access | Times Cited: 53
Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19
Roman Maslennikov, В. Т. Ивашкин, Ekaterina Vasilieva, et al.
Pulmonary Pharmacology & Therapeutics (2021) Vol. 69, pp. 102039-102039
Open Access | Times Cited: 41
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19
Khan Sharun, Ruchi Tiwari, Mohd I. Yatoo, et al.
Narra J (2022) Vol. 2, Iss. 3, pp. e92-e92
Open Access | Times Cited: 34
Immunotherapies and immunomodulatory approaches in clinical trials - a mini review
Mohd. Iqbal Yatoo, Zeenat Hamid, IZHAR AHMAD RATHER, et al.
Human Vaccines & Immunotherapeutics (2021) Vol. 17, Iss. 7, pp. 1897-1909
Open Access | Times Cited: 32
Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib
Sz‐Tsan Wang, Chih‐Wei Tseng, Chia‐Wen Hsu, et al.
International Journal of Rheumatic Diseases (2021) Vol. 24, Iss. 11, pp. 1362-1369
Closed Access | Times Cited: 30
Existing Drugs Considered as Promising in COVID-19 Therapy
Edyta Janik, Marcin Niemcewicz, Marcin Podogrocki, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5434-5434
Open Access | Times Cited: 29
Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
Domingo A. Pascual‐Figal, Aychel E Roura-Piloto, Encarnación Moral‐Escudero, et al.
International Journal of General Medicine (2021) Vol. Volume 14, pp. 5517-5526
Open Access | Times Cited: 29
Are Patients With Autoimmune Cytopenias at Higher Risk of COVID-19 Pneumonia? The Experience of a Reference Center in Northern Italy and Review of the Literature
Wilma Barcellini, Juri Alessandro Giannotta, Bruno Fattizzo
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 28
Stem cell therapies and benefaction of somatic cell nuclear transfer cloning in COVID-19 era
Birbal Singh, Gorakh Mal, Vinod Verma, et al.
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis
Carlos J. Toro‐Huamanchumo, Jerry K. Benites‐Meza, Carlos S. Mamani-García, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2615-2615
Open Access | Times Cited: 21
Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial
Ali Saeedi‐Boroujeni, Roohangiz Nashibi, Ata Ghadiri, et al.
Archives of Medical Research (2022) Vol. 53, Iss. 4, pp. 368-377
Open Access | Times Cited: 19
Macrophage-derived cytokines in pneumonia: Linking cellular immunology and genetics
Marina Dukhinova, Elena K. Kokinos, Polina Kuchur, et al.
Cytokine & Growth Factor Reviews (2020) Vol. 59, pp. 46-61
Open Access | Times Cited: 30
Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19
Jie Geng, Feng Wang, Zhiwei Huang, et al.
Cytokine (2021) Vol. 143, pp. 155544-155544
Open Access | Times Cited: 25
Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)
Abdiel Absalón‐Aguilar, Marina Rull‐Gabayet, Alfredo Pérez‐Fragoso, et al.
Journal of General Internal Medicine (2021) Vol. 37, Iss. 1, pp. 4-14
Open Access | Times Cited: 25
COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2
Syed Muhammad Ismail Shah, Farah Yasmin, Roha Saeed Memon, et al.
Brain and Behavior (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 16
Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review
Vincenzo Lariccia, Simona Magi, Tiziano Serfilippi, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 12, pp. 4021-4021
Open Access | Times Cited: 26
Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges
Fares E.M. Ali, Zuhair M. Mohammedsaleh, Mahmoud Ali, et al.
World Journal of Gastroenterology (2021) Vol. 27, Iss. 15, pp. 1531-1552
Open Access | Times Cited: 22
Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells
Carolina Q. Sacramento, Natália Fintelman-Rodrigues, Suelen da Silva Gomes Dias, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 374-374
Open Access | Times Cited: 15
Targeting cytokine storm as the potential anti-viral therapy: Implications in regulating SARS-CoV-2 pathogenicity
Subhasish Maity, Ayantika Santra, Ananda Vardhan Hebbani, et al.
Gene (2023) Vol. 881, pp. 147612-147612
Closed Access | Times Cited: 8
An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic
Edi Dharmana, Juliane Brun, Michelle L. Hill, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 354-354
Open Access | Times Cited: 8
Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study
Mette Louise Andersen, Floor Dijkstra Zegers, Line Riis Jølving, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105031-105031
Open Access | Times Cited: 7
Immune mechanisms in cancer patients that lead to poor outcomes of SARS-CoV-2 infection
Muhammad Latif, Sudhanshu Shukla, Perla M. Del Río Estrada, et al.
Translational research (2021) Vol. 241, pp. 83-95
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top